ADXN.SW

Addex Therapeutics Ltd

ADXN.SW, Switzerland

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

https://www.addextherapeutics.com

Stock Price

CHF0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ADXN.SW
stock
ADXN.SW

ADXN.SW Addex Therapeutics (SIX) pre-market CHF0.0564 vol 1.51M: watch liquidity Meyka

Read more →
ADXN.SW
stock
ADXN.SW

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia Yahoo Finance UK

Read more →

Showing 2 of 5

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

SELL

$

Analyst Picks

Strong Buy

0

Buy

0

Hold

0

Sell

1

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-26.47 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-21.52 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,793.85 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.23

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Addex Therapeutics Ltd

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0

Latest Release

Date

2025-09-30

EPS Actual

-0.0183

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

CHF 0

Cost Of Revenue

CHF 0

Gross Profit

CHF 0

Operating Expenses

CHF 0

Operating Income

CHF 0

Interest Expense

CHF 0

Pretax Income

CHF 0

Net Income

CHF 0

Income Tax Expense

CHF 0

EBITDA

CHF 0

Total Other Income Expense Net

CHF 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

CHF 0

Short Term Investments

CHF 0

Receivables

CHF 0

Inventories

CHF 0

Total Current Assets

CHF 0

Property Plant Equipment

CHF 0

Total Assets

CHF 0

Payables

CHF 0

Short Term Debt

CHF 0

Long Term Debt

CHF 0

Total Liabilities

CHF 0

Equity

CHF 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

CHF 0

Depreciation

CHF 0

Change In Working Capital

CHF 0

Cash From Operations

CHF 0

Capital Expenditures

CHF 0

Cash From Investing

CHF 0

Cash From Financing

CHF 0

Net Change In Cash

CHF 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.